Status:
UNKNOWN
Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke
Lead Sponsor:
Chang Gung Memorial Hospital
Collaborating Sponsors:
National Taiwan University Hospital
Chiayi Christian Hospital
Conditions:
Diabetes Mellitus
Stroke
Eligibility:
All Genders
20-99 years
Phase:
PHASE2
Brief Summary
Introduction: An optimal combination of antidiabetic drugs for diabetic patients with ischemic stroke is not well-established. The objective of this randomized trial is to evaluate whether combination...
Eligibility Criteria
Inclusion
- Ischemic stroke within 3 months of randomization
- Type 2 diabetes mellitus and Hba1C \> 7.0% and under metformin therapy currently or previously
- Estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2
- Age ≥ 20 y at study entry
- Ability and willingness to provide informed consent
Exclusion
- History of congestive heart failure (NYHA class 1-4)
- History of bladder cancer
- History of repeated (\> 2 episodes) urinary tract infection or genital tract infection
- Irreversible medical conditions with predicted survival \< 1 years
- Current use of an insulin
- Current use of a glucagon-like peptide-1 receptor agonist
- Current use of pioglitazone or an SGLT-2 inhibitor
Key Trial Info
Start Date :
September 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04419337
Start Date
September 15 2019
End Date
January 31 2024
Last Update
March 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital, Chiayi Branch
Chiayi City, Taiwan, 613